ALLO-647

Phase 2Cell therapy

AAllogene Therapeutics

ALLO-647 is one of 102 biologic programs targeting Clear Cell Renal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clear Cell Renal Cell CarcinomaActive, not recruiting

Multiple MyelomaTerminated

Chronic Lymphocytic LeukemiaActive, not recruiting

Clear Cell Renal Cell CarcinomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Terminated

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

Ninlaro

Takeda

Phase 3

18 3

Venclexta

AbbVie

Phase 3

17 4

Keytruda

Merck & Co.

Phase 3

17 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 6

Opdivo

Bristol-Myers Squibb

Phase 3

11 7

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 8

Treanda

AAzurity Pharmaceuticals

Phase 3

19 9

Neulasta

Amgen

Phase 3

5 10

Elranatamab

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Multiple Myeloma

NCT04093596

Q2 2029

Phase 1/2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT04416984

Q1 2030

Phase 1Active, not recruiting

Clear Cell Renal Cell Carcinoma

NCT04696731

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·AAllogene Therapeutics·Phase 1/2·NCT05000450·6 enrolled

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Active, not recruiting·AAllogene Therapeutics·Phase 1·NCT04093596·132 enrolled

Chronic Lymphocytic Leukemia1 trial

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active, not recruiting·AAllogene Therapeutics·Phase 1/2·NCT04416984·160 enrolled

Follicular Lymphoma1 trial

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Completed·AAllogene Therapeutics·Phase 1·NCT03939026·50 enrolled

Lymphoma1 trial

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Terminated·AAllogene Therapeutics·Phase 2·NCT05714345·2 enrolled

Clear Cell Renal Cell Carcinoma1 trial

A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Active, not recruiting·AAllogene Therapeutics·Phase 1·NCT04696731·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ALLO-647. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALLO-647 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALLO-647. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allogene Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: AAllogene Therapeutics

ALLO-647

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2029

Q1 2030

Trials by Indication[1]

Multiple Myeloma2 trials

Chronic Lymphocytic Leukemia1 trial

Follicular Lymphoma1 trial

Lymphoma1 trial

Clear Cell Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News